FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Eugia US Tirofiban Hydrochloride Injection 5 mg/100 mL Recall

Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container…

Eugia US LLC · East Windsor, NJ

Risk level
Class II
Reported by FDA
May 7, 2025
Recall ID
D-0389-2025
Check your lot numberHow we source this data

Summary

Eugia US recalled Tirofiban Hydrochloride Injection 5 mg/100 mL starting Apr 21, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0389-2025 on May 7, 2025. Reason: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances. Status: Ongoing.

Why it was recalled

Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

Product description

Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-429-01

Lot numbers, UPCs & expiration codes

Lot #: 3TF24002A, Exp 11/30/2026

Where it was sold

USA nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0389-2025
Classification
Class II
Status
Ongoing
Recall initiated
Apr 21, 2025
FDA report date
May 7, 2025
Quantity
18,867 bags
Recall type
Voluntary: Firm initiated
Recalling firm
Eugia US LLC

Original FDA data

Every field from FDA enforcement report D-0389-2025, exactly as published.

Show all FDA fields
City
East Windsor
State
NJ
Status
Ongoing
Country
United States
Event ID
96718
Address
279 Princeton Hightstown Rd
Code information
Lot #: 3TF24002A, Exp 11/30/2026
Postal code
08520-1401
Report date
May 7, 2025
Product type
Drugs
Recall number
D-0389-2025
Classification
Class II
Recalling firm
Eugia US LLC
Product quantity
18,867 bags
Reason for recall
Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-429-01
Distribution pattern
USA nationwide.
Recall initiation date
Apr 21, 2025
Initial firm notification
Letter
Center classification date
Apr 25, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0389-2025, published May 7, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls